Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting
(Adnkronos) – In the ASCO Developmental Therapeutics – Immunotherapy Session, Dr. Howard Safran presents encouraging data on Dragonfly’s phase 1/2 study of DF1001, an immune engaging TriNKET® targeting HER2 in patients with
